Study adds support for oral rabies vaccination in dogs
Bottom line
A new paper in Veterinary Immunology and Immunopathology adds to the evidence that the third-generation oral rabies vaccine strain SPBN GASGAS can generate a meaningful immune response in dogs, including free-roaming populations that are often missed by injectable campaigns. The study pooled serology from longitudinal and cross-sectional work conducted under controlled and field conditions, addressing a long-running concern in rabies control: whether oral vaccination produces protective humoral immunity reliably enough in local dog populations. The findings build on earlier challenge and follow-up studies showing strong survival after rabies challenge, field immunogenicity in Namibia and Bali, and long-term immune responses in Thai dogs that were reported as non-inferior to inactivated vaccine benchmarks in immunobridging work. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, especially those involved in public health, shelter medicine, or international rabies control, the paper strengthens the case for oral rabies vaccination as a complement, not a replacement, to parenteral vaccination in hard-to-reach dogs. WHO says canine campaigns need more than 70% coverage to interrupt transmission, and oral vaccination is increasingly viewed as a practical way to close that gap in free-roaming dog populations where handling for injection is difficult or unsafe. WOAH has also highlighted SPBN GASGAS as the first oral rabies vaccine for dogs described in the scientific literature, underscoring growing institutional support for this approach. (who.int)
What to watch: Watch for how these immunogenicity data are used in future regulatory, programmatic, and field-deployment decisions as countries refine dog rabies elimination strategies. (iris.who.int)
Key facts
- Study topic
- Immunogenicity of the third-generation oral rabies vaccine SPBN GASGAS in dogs
- Journal
- Veterinary Immunology and Immunopathology
- Study design
- Pooled serology from longitudinal and cross-sectional studies
- Study conditions
- Controlled and field conditions
- Main question
- Whether oral vaccination produces protective humoral immunity reliably in local dog populations
- Population of interest
- Free-roaming dogs
- Context
- Oral vaccination is described as a complement, not a replacement, for parenteral vaccination
- Related evidence
- Earlier studies reported strong survival after rabies challenge, field immunogenicity in Namibia and Bali, and long-term immune responses in Thai dogs
A new Veterinary Immunology and Immunopathology study is the latest piece of evidence supporting SPBN GASGAS, a third-generation oral rabies vaccine, as a credible tool for vaccinating dogs that are difficult to reach with standard injections. The paper focuses on immunogenicity, analyzing serologic responses in dogs across both longitudinal and cross-sectional studies, and directly addresses skepticism about whether oral vaccination can produce dependable protection in local free-roaming dog populations. (pubmed.ncbi.nlm.nih.gov)
That question matters because oral rabies vaccination for dogs has been discussed for years as a way to supplement conventional mass vaccination, particularly in settings where dogs can’t be safely restrained. WHO says dog vaccination coverage needs to exceed 70% to stop transmission, but field programs often struggle to reach that threshold in free-roaming populations. A 2020 CDC review argued that oral vaccines could help close those coverage gaps, while WOAH said in 2023 that oral vaccination of dogs could be pivotal to the “Zero by 30” push to end dog-mediated human rabies deaths. (who.int)
SPBN GASGAS has been accumulating evidence for several years. In a controlled efficacy study published in 2023, 24 of 25 vaccinated dogs survived rabies challenge about six months after receiving vaccine bait, while all 10 controls died; all vaccinated dogs seroconverted by ELISA, although fewer met the traditional 0.5 IU/mL threshold on RFFIT, a finding that helped fuel debate over which serologic markers best predict protection after oral vaccination. Later immunobridging work reported that long-term immunity after oral SPBN GASGAS vaccination was non-inferior to responses seen with an inactivated rabies vaccine, with follow-up extending to roughly 1,100 days in Thai dogs. (pubmed.ncbi.nlm.nih.gov)
Field studies have pointed in the same direction. Research in Namibia found the vaccine immunogenic in local free-roaming dogs under campaign conditions, and a Bali study reported immune responses after oral administration in local dogs there as well. WHO has separately highlighted Namibia’s use of oral rabies vaccines for dogs within a One Health control strategy, reflecting how this work is moving beyond laboratory proof-of-concept and into real campaign settings. (pubmed.ncbi.nlm.nih.gov)
Industry and institutional signals also suggest this is an area to watch. Ceva has expanded its oral rabies vaccine portfolio through acquisition activity, and WOAH has publicly framed SPBN GASGAS as the first oral rabies vaccine for dogs documented in the literature. At the same time, the broader expert view remains measured: oral vaccination is generally presented as an adjunct for inaccessible dogs, not a substitute for routine injectable vaccination where handling is feasible and legal frameworks are already established. (ceva.com)
Why it matters: For veterinary professionals, the practical significance is less about replacing the exam-room rabies shot and more about expanding the toolbox for population-level control. In regions where free-roaming dogs sustain transmission, better evidence that oral vaccination produces durable, predictive immune responses could support campaign design, procurement decisions, and policy discussions around licensure and field use. It also matters for occupational safety: oral baiting can reduce the need for physical restraint in difficult dogs, lowering bite risk for vaccinators while potentially improving campaign coverage. (wwwnc.cdc.gov)
There are still important caveats. The U.S. rabies framework remains built around licensed parenteral vaccination and local legal requirements, and CDC guidance for veterinarians continues to emphasize use of licensed rabies vaccines according to state and local rules. More broadly, oral vaccine programs in dogs still depend on bait acceptance, campaign logistics, public communication, and regulatory confidence in correlates of protection, especially when ELISA and neutralization assays do not align perfectly. (cdc.gov)
What to watch: The next step is whether accumulating immunogenicity and field-effectiveness data translate into wider regulatory acceptance, formal program guidance, and scaled deployment in endemic countries pursuing dog-mediated rabies elimination. (woah.org)